[{"Assets_0_Q3_USD":160380000.0,"EarningsPerShareBasic_1_Q3_USD":-0.5,"EarningsPerShareBasic_3_Q3_USD":-1.34,"EarningsPerShareDiluted_1_Q3_USD":-0.5,"EarningsPerShareDiluted_3_Q3_USD":-1.34,"NetIncomeLoss_1_Q3_USD":-12308000.0,"NetIncomeLoss_3_Q3_USD":-30993000.0,"StockholdersEquity_0_Q3_USD":-132422000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q3_shares":24845364.0,"WeightedAverageNumberOfDilutedSharesOutstanding_3_Q3_shares":23196293.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q3_shares":24845364.0,"WeightedAverageNumberOfSharesOutstandingBasic_3_Q3_shares":23196293.0,"Ticker":"RETA","CIK":"1358762","name":"REATA PHARMACEUTICALS INC","OfficialName":"Reata Pharmaceuticals Inc. Class A Common Stock","form":"10-Q","period":"20170930","fy":"2017.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1148907684.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20171113"}]